Taking a step back and looking at this situation, it is
Taking a step back and looking at this situation, it is easy to have a cautious attitude mostly because the SP is so far away from the drug's very near revenue potential and growing market opportunities. But, if I look at the fact that this is a one product company the has been in fund raising mode for 7-8 years with no revenue and on the OTC, the SP is somewhat explainable. In any other biotech, it would be natural to worry that some bad trial event might happen, a better drug gets to market first or their is a lack of any communication from the mgmt team, we don't have those worries. Cytodyn is updating us weekly, sometimes daily. We get to have a lot of words to dissect beyond actual meaning and the pressure is huge to get this SP to reflect the drug's value.
The growing list of indications is something most every drug does not experience - outside research is driving this growing list. Mgmt is not just throwing indications out there to create buzz for financing. It would be stupid to not publicize and pursue all opportunities for this drug.
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding the Social Casino Landscape The online gaming industry has witnessed a remarkable evolution, particularly in the realm of social casinos. These platforms allow players to engage in casino-style games while offering ways to cash out real money through inventive sweepstakes models. The recent report from a leading analyst group highlights key trends, new...
Continue Reading
TCL Electronics Expects Substantial Growth in Profits TCL Electronics Holdings Limited (01070.HK) has recently announced an impressive profit expectation for the upcoming year. The company anticipates an adjusted profit attributable to owners of the parent to grow by approximately 62% to 112% compared to the previous year. This projection comes from a preliminary review...
Continue Reading
iRhythm Technologies to Release Q2 Financial Results iRhythm Technologies, Inc. (NASDAQ: IRTC) stands at the forefront of digital healthcare, dedicated to developing reliable solutions that effectively identify, prevent, and predict various health issues. The company has announced its plans to release the financial results for the second quarter of 2025 on July 31, right...
Continue Reading
Hanwha Life's Ambitious U.S. Acquisition Hanwha Life, noted for being the first Korean insurance provider, has taken a significant step by acquiring a 75% stake in Velocity Clearing, LLC. This acquisition presents a unique opportunity for the company to venture into the North American capital markets, which have proven to be pivotal in global finance. Capitalizing on...
Continue Reading
Essent Group's Stock Performance Reaches New Heights Essent Group Ltd. (NYSE: ESNT) has experienced a significant surge in market confidence, with its stock price climbing to an all-time high of $64.7. This achievement marks a key milestone for the mortgage insurance company and underscores its strong performance over the past year. Investors have reacted positively to...
Continue Reading
